source
- ADC Therapeutics shares plunge as Phase 3 trial of Zynlonta shows high death rate despite efficacy gainADC Therapeutics reported Phase 3 data for Zynlonta combined with rituximab in a hard-to-treat blood cancer. The trial met its primary endpoint by extending progression-free survival versus standar…
- Supreme Court rules generic maker Hikma does not infringe Amarin patents, easing skinny-label lawsuitsThe U.S. Supreme Court issued a unanimous decision that Hikma Pharmaceuticals did not violate patents owned by Amarin. The high court overturned a lower court ruling that had favored the brand name…